These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34180282)

  • 41. Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients.
    Curran A; Rojas J; Cabello A; Troya J; Imaz A; Domingo P; Martinez E; Ryan P; Górgolas M; Podzamczer D; Knobel H; Gutiérrez F; Ribera E
    J Antimicrob Chemother; 2016 Dec; 71(12):3510-3514. PubMed ID: 27591292
    [TBL] [Abstract][Full Text] [Related]  

  • 42. APOBEC-Induced Mutations at Initiation of Cabotegravir + Rilpivirine for Two Patients Infected by HIV-1 Subtype CRF02: The Interest of Systematic Genotyping.
    Wembulua BS; Valin N; Lambert-Niclot S; Nerozzi-Banfi E; Chiarabini T; Meynard JL; Lacombe K
    J Acquir Immune Defic Syndr; 2023 Mar; 92(3):e17-e18. PubMed ID: 36729654
    [No Abstract]   [Full Text] [Related]  

  • 43. Design strategies for long-acting anti-HIV pharmaceuticals.
    Sang Y; Ding L; Zhuang C; Chen F
    Curr Opin Pharmacol; 2020 Oct; 54():158-165. PubMed ID: 33176247
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cabotegravir (Apretude) for HIV-1 pre-exposure prophylaxis.
    Med Lett Drugs Ther; 2022 Feb; 64(1644):29-31. PubMed ID: 35171897
    [No Abstract]   [Full Text] [Related]  

  • 46. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
    Aboud M; Orkin C; Podzamczer D; Bogner JR; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Blair EA; Adkison K; Underwood M; Matthews JE; Wynne B; Vandermeulen K; Gartland M; Smith K
    Lancet HIV; 2019 Sep; 6(9):e576-e587. PubMed ID: 31307948
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
    Sculier D; Gayet-Ageron A; Battegay M; Cavassini M; Fehr J; Hirzel C; Schmid P; Bernasconi E; Calmy A;
    BMC Infect Dis; 2017 Jul; 17(1):476. PubMed ID: 28683720
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Background factors in people living with HIV in Japan who switch to cabotegravir plus rilpivirine: A pilot study.
    Adachi E; Ikeuchi K; Koga M; Yotsuyanagi H
    J Infect Chemother; 2023 Jan; 29(1):109-111. PubMed ID: 36116718
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cabotegravir and rilpivirine for the treatment of HIV.
    Rial-Crestelo D; Pinto-Martínez A; Pulido F
    Expert Rev Anti Infect Ther; 2020 May; 18(5):393-404. PubMed ID: 32164474
    [No Abstract]   [Full Text] [Related]  

  • 50. The optimum implementation of long-acting injectable cabotegravir-rilpivirine in sub-Saharan Africa.
    Dawood H
    Lancet Glob Health; 2021 May; 9(5):e563-e564. PubMed ID: 33770512
    [No Abstract]   [Full Text] [Related]  

  • 51. Human Immunodeficiency Virus Type 1 RNA Levels in Rectal and Seminal Compartments After Switching to Long-Acting Cabotegravir Plus Rilpivirine: A Longitudinal Study.
    Masiá M; Fernández-González M; Agulló V; Mascarell P; Padilla S; García-Abellán J; Gutiérrez F
    Clin Infect Dis; 2023 Feb; 76(3):e748-e751. PubMed ID: 35986671
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.
    McGowan I; Dezzutti CS; Siegel A; Engstrom J; Nikiforov A; Duffill K; Shetler C; Richardson-Harman N; Abebe K; Back D; Else L; Egan D; Khoo S; Egan JE; Stall R; Williams PE; Rehman KK; Adler A; Brand RM; Chen B; Achilles S; Cranston RD
    Lancet HIV; 2016 Dec; 3(12):e569-e578. PubMed ID: 27658864
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-acting drugs and formulations for the treatment and prevention of HIV infection.
    Flexner C; Owen A; Siccardi M; Swindells S
    Int J Antimicrob Agents; 2021 Jan; 57(1):106220. PubMed ID: 33166693
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rilpivirine long-acting for the prevention and treatment of HIV infection.
    Ferretti F; Boffito M
    Curr Opin HIV AIDS; 2018 Jul; 13(4):300-307. PubMed ID: 29794818
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults.
    Ho S; Wong JG; Ng OT; Lee CC; Leo YS; Lye DCB; Wong CS
    AIDS Res Ther; 2020 May; 17(1):23. PubMed ID: 32438914
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rilpivirine Plasma and Cervicovaginal Concentrations in Women During Pregnancy and Postpartum.
    Eke AC; Chakhtoura N; Kashuba A; Best BM; Sykes C; Wang J; Stek AM; Smith E; Calabrese S; Capparelli EV; Mirochnick M;
    J Acquir Immune Defic Syndr; 2018 Jul; 78(3):308-313. PubMed ID: 29528944
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment.
    Alberton F; Nozza S; Raccagni AR; Galli L; Spagnuolo V; Bossolasco S; Cernuschi M; Canetti D; Hasson H; Castagna A; Gianotti N
    J Med Virol; 2023 Jan; 95(1):e28330. PubMed ID: 36415058
    [No Abstract]   [Full Text] [Related]  

  • 58. Miniature mass spectrometer-based point-of-care assay for cabotegravir and rilpivirine in whole blood.
    Pandey S; Hu Y; Bushman LR; Castillo-Mancilla J; Anderson PL; Cooks RG
    Anal Bioanal Chem; 2022 May; 414(11):3387-3395. PubMed ID: 35169905
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cabotegravir-rilpivirine treatment initiation in a nonvirologically suppressed patient.
    Barnett SK; Armas-Kolostroubis L; Sension M; Riedel DJ
    AIDS; 2022 Aug; 36(10):1475-1476. PubMed ID: 35876710
    [No Abstract]   [Full Text] [Related]  

  • 60. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.
    Crauwels H; van Heeswijk RP; Stevens M; Buelens A; Vanveggel S; Boven K; Hoetelmans R
    AIDS Rev; 2013; 15(2):87-101. PubMed ID: 23681436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.